Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker ISCO · OTC · DE
25/100
International Stem Cell CORP is a U.S. business entity operating within the Pharmaceutical Preparations sector (SIC 2834). Publicly traded on the OTC under the ticker symbol ISCO, the company is incorporated in Delaware. Based on SEC EDGAR filings, ISCO reported fiscal year 2024 revenue of $9.1M, reflecting a year-over-year growth of 16.6%. Our proprietary Semantic Risk Score of 18 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 2834 classification, International Stem Cell CORP serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
International Stem Cell CORP (ISCO) — Key efficiency & solvency metrics · FY2024
Operating Margin
Sector avg: -60.64%
Net Margin
Sector avg: -68.94%
Debt-to-Equity
Sector avg: 1.36
Current Ratio
Sector avg: 4.84
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: +16.6% | $9.1M | $1.89B | ▼ Lagging |
| Net IncomeYoY: -59.5% | $-209,000 | — | — |
| Operating MarginOperating income as % of revenue | -0.7% | -60.64% | ▲ Outperform |
| Net MarginNet income as % of revenue | -2.3% | -68.94% | ▲ Outperform |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | -1.22 | 1.36 | ▲ Stable |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 0.76 | 4.84 | ▼ Lagging |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 311 companies in SIC 2834.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
STEM CELL THERAPEUTIC OUTCOMES DATABASE (SCTOD) - ESTABLISH AND MAINTAIN A SCIENTIFIC DATABASE OF INFORMATION RELATING TO PATIENTS WHO HAVE BEEN RECIPIENTS OF A STEM CELL THERAPEUTICS PRODUCT (INCLUDING BONE MARROW OR CORD BLOOD) FROM A DONOR.
IGF::CT::IGF STEM CELL THERAPEUTIC OUTCOMES DATABASE (SCTOD)
IGF::CT::IGF CRITICAL FUNCTION MAINTAIN THE STEM CELL THERAPEUTIC OUTCOMES DATABASE WHICH COLLECTS AND MAINTAINS INFORMATION RELATED TO PATIENTS WHO HAVE RECEIVED STEM CELL THERAPEUTIC PRODUCTS IN A STANDARDIZED ELECTRONIC FORMAT
IGF::OT::IGF STEM CELL PROCESSING FOR TRANSPLANT AT NASHVILLE VAMC.
UTILIZING THE CONTRACTORS TECHNOLOGY, HUMAN INDUCED PLURIPOTENT STEM CELLS WILL UNDERGO DIFFERENTIATION TO PRE-MEGAKARYOCYTES (PREMK+), WHICH ARE STOCKPILED THROUGH CRYOPRESERVATION. FROZEN PREMK+ ARE THAWED AND FURTHER DIFFERENTIATED TO MATURE MEGAK
PRODUCTION OF LARGE POPULATIONS OF HEMATOPOIETIC STEM CELLS (HSCS) IN MICROGRAVITY TO TREAT SERIOUS MEDICAL CONDITIONS INCLUDING BLOOD CANCERS (LEUKEMIAS, LYMPHOMAS, MULTIPLE MYELOMA), FATAL BLOOD DISORDERS, AND SEVERE IMMUNE DISEASES.
THE PURPOSE OF THIS RESOURCE IS TO BUILD AND SUPPORT A CRITICAL NATIONAL BIOREPOSITORY OF NORMAL AND LUNG DISEASESPECIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS), AS WELL AS THEIR DIFFERENTIATED PROGENY, TO SERVE THE LUNG RESEARCH COMMUNITY.
EXTENSION OF PREVIOUS STUDIES ON TERIPARATIDE TO DETERMINE THE EXTENT TO WHICH IT MITIGATES RADIATION-INDUCED THROMBOCYTOPENIA AND IMPROVES BLOOD-FORMING STEM CELL NUMBERS
IN-SPACE PRODUCTION OF STEM CELL THERAPIES
IGF::OT::IGF R&D- NANOEMULSION FORMULATION AND IND-ENABLING STUDIES OF A NOVEL CENTER STEM CELL CYTOTOXIC AGENT
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 595 peers in Pharmaceutical Preparations (SIC 2834)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
America's #1 crypto exchange. Buy Bitcoin, Ethereum & 200+ coins.
Get Started Free →Affiliate link · sprytne.com may earn a commission
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →